# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Capital One analyst Tim Chiang initiates coverage on Heron Therapeutics (NASDAQ:HRTX) with a Overweight rating and announces...
Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $5 price target.
Heron Therapeutics' Q4 2023 results: Beat EPS consensus at $(0.07), $34.23 million sales, up 14% Y/Y. Strong momentum in ac...
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported b...
Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and raises the price target from $4 to $5.